MetaCap

Annovis Bio (ANVS) vs Corbus Pharmaceuticals (CRBP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Annovis Bio (ANVS) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 81.2% versus a loss of 82.8%. Over five years, CRBP leads with a -92.2% price change compared with -97.2% for ANVS. Annovis Bio is the larger company by market cap ($44.1 million vs $42.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANVS-81.23%CRBP-82.85%
+40%-24%-89%
Nov 21, 20251 yearNov 20, 2026
ANVS-97.38%CRBP-92.63%
+130%+11%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANVS versus CRBP key metrics
MetricANVSCRBP
Share price$0.7113$2.06
Market cap$44.12M$42.45M
1-day change-4.96%-15.40%
YTD return-79.44%-74.69%
1-year return-81.23%-82.85%
5-year return-97.24%-92.23%
EPS (TTM)$-1.55$-6.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-28.85M$-78.54M
52-week high$5.50$12.88
52-week low$0.62$2.01
Distance from 52-week high-87.07%-84.01%
Analyst consensusnonestrong_buy
Avg. price target upside+1376.17%+1551.94%
Average volume1.82M1.11M
Shares outstanding62.02M20.61M
Employees736
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Annovis Bio

ANVS stock →

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Corbus Pharmaceuticals

CRBP stock →

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees

ANVS vs CRBP FAQ

Which is bigger, Annovis Bio or Corbus Pharmaceuticals?

Annovis Bio (ANVS) is larger, with a market capitalization of $44.12M compared with $42.45M for Corbus Pharmaceuticals (CRBP).

Which stock has performed better over the past year, ANVS or CRBP?

ANVS returned -81.23% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.

Are Annovis Bio and Corbus Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons